Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Development of effective treatments for high-grade glioma (HGG) is hampered by (1) the blood–brain barrier (BBB), (2) an infiltrative growth pattern, (3) rapid development of therapeutic resistance, and, in many cases, (4) dose-limiting toxicity due to systemic exposure. Convection-enhanced delivery...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwagwu, Chibueze D., Immidisetti, Amanda V., Jiang, Michael Y., Adeagbo, Oluwasegun, Adamson, David C., Carbonell, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071501/
https://www.ncbi.nlm.nih.gov/pubmed/33921157
http://dx.doi.org/10.3390/pharmaceutics13040561
Descripción
Sumario:Development of effective treatments for high-grade glioma (HGG) is hampered by (1) the blood–brain barrier (BBB), (2) an infiltrative growth pattern, (3) rapid development of therapeutic resistance, and, in many cases, (4) dose-limiting toxicity due to systemic exposure. Convection-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and increase therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas.

Ejemplares similares